Latest Biotech News

Biogen struck a deal to buy RayThera for up to $1 billion, aiming to add a portfolio of early immunology assets to its pipeline. The acquisition is structured with an undisclosed upfront payment...

cAMPfield Therapeutics raised a $180 million Series A to develop prifemilast, an oral PDE4B-selective therapy for inflammatory bowel disease. The company said the program is intended as an...

ADC Therapeutics reported a stumbling block for Zynlonta (loncastuximab tesirine) after Phase 3 results from LOTIS-5 showed higher fatal adverse events in the treatment arm. The antibody-drug...

The FDA extended the comment period for its AI-powered real-time clinical trial (RTCT) pilot, giving sponsors and CROs more time to respond to how AI should be used to report endpoint data as...

NCCN updated its guidelines to recommend cerebrospinal fluid (CSF)-based molecular tumor profiling for high-grade glioma and glioblastoma when tissue biopsy is not feasible. The recommendation...

Novo Nordisk is stepping up capacity and operational reach through new investments tied to manufacturing expansion. The company said it has invested about $380 million to expand its manufacturing...

F2G and Shionogi reported positive Phase 3 results for olorofim, an oral antifungal being developed for invasive aspergillosis. The companies said the drug demonstrated non-inferiority versus an...

Beam Therapeutics received FDA IND clearance for BEAM-304, advancing a liver-targeted base editing program for phenylketonuria (PKU). The company said BEAM-304 uses a lipid-nanoparticle (LNP)...

Jazz Pharmaceuticals expanded its immuno-oncology discovery footprint by launching a large preclinical collaboration with AbCellera focused on T-cell engaging multispecific antibodies for...

The FDA reversed course on uniQure’s Huntington’s disease gene therapy, clearing a path for the company to submit a marketing application for accelerated approval. UniQure said regulators would...

Biogen agreed to acquire RayThera in a backloaded deal valued up to $1 billion, aiming to add preclinical immunology assets to its pipeline. The companies said the transaction would bring...

Novocure reported that its electric fields therapy, when combined with chemoradiation, failed to extend survival in a key phase 3 glioblastoma study. The company said the negative result reduces...

ADC Therapeutics disclosed that its antibody-drug conjugate Zynlonta hit a stumbling block after confirmatory phase 3 results in relapsed or refractory diffuse large B-cell lymphoma. The LOTIS-5...

Kardigan raised $400 million in an upsized IPO to fund development of three clinical-stage cardiovascular drugs. The offering came in about 14% above expectations, with the company positioning the...

The National Comprehensive Cancer Network updated guidelines to recommend cerebrospinal fluid (CSF)-based molecular tumor profiling for high-grade glioma and glioblastoma when tissue biopsy is not...

The FDA extended the public comment period for its AI-powered real-time clinical trial (RTCT) pilot, pushing feedback due to June 29. The agency said it granted the additional time after requests...

Takeda reported that its oral TYK2 inhibitor zasocitinib (TAK-279) beat Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a head-to-head Phase 3 readout for moderate-to-severe plaque psoriasis....

Air transportation for organs is expanding alongside new logistics guidance, creating a need for operational tools that coordinate distributed teams. Coverage highlighted how the transition toward...

Volition announced a collaboration with Sysmex to optimize its circulating nucleosome-based Nu.Q NETs H3.1 assay on the Sysmex system. The test quantifies neutrophil extracellular traps (NETs) via...

Jazz Pharmaceuticals and AbCellera announced a preclinical option-and-license collaboration to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies for GI cancers...